ArticleSurgical endoscopy2025
Multicenter analysis of the efficacy and factors related to recurrence of endoscopic sclerotherapy for internal hemorrhoids: a large-sample, retrospective cohort study.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cap-assisted endoscopic sclerotherapy for bleeding-predominant grade III hemorrhoids: efficacy and risk factor analysis focusing on two dimensions of bleeding score.Techniques in coloproctology · 2026Observational
- Early hemodynamic changes following endoscopic sclerotherapy for hemorrhoidal disease assessed by transperineal ultrasound and their relationship with clinical outcomes.International journal of colorectal disease · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInternal hemorrhoids are common, and while endoscopic sclerotherapy is emerging as a treatment, large-scale, multi-center data on its efficacy, safety, and recurrence rates are lacking. We summarized three-center large-sample endoscopic hemorrhoid sclerotherapy data, assess efficacy, complications, recurrence, and analyze recurrence factors (severity, lifestyle).
methodsA retrospective analysis of patients with internal hemorrhoids treated with endoscopic sclerotherapy at three centers from December 2018 to December 2022 was conducted. Clinical and follow-up data were collected to assess hemorrhoid grading, treatment efficacy, complications, and recurrence rates. The recurrence rate, recurrence time, and related factors for different hemorrhoid grades were analyzed.
resultsA total of 1147 patients underwent the procedure: 637 at Shenzhen Hospital of Southern Medical University, 177 at No. 964 Hospital, and 333 at Third Affiliated Hospital, Army Medical University. The overall effective rate was 92.85% (1065/1147). Postoperative safety measures showed the effective group had significantly lower pain (1 (0,1) vs. 2 (2,3)), bleeding (0 (0,1) vs. 2 (1,3)), and urination scores (0 (0,0) vs. 0 (0,1)) compared to the ineffective group. The overall recurrence rate was 12.21% (130/1065), with follow-up periods ranging from 3 to 49 months (mean: 25.61 ± 13.23 months). Recurrence time was earlier with increasing hemorrhoid grade (p < 0.05). Temporal analysis revealed that for Grades I, II, and III, recurrence rates within one year were 28, 39.78, and 75%, respectively, vs 72, 60.22, and 25% beyond 1 year. Multivariate logistic regression indicated higher BMI and lack of exercise were associated with increased recurrence (p < 0.05), while lower hemorrhoid grade, working position, and dietary habits were protective factors (p < 0.05).
conclusionEndoscopic sclerotherapy is a safe and effective treatment for internal hemorrhoids with a low short-term recurrence rate. Key factors influencing recurrence include BMI, exercise, hemorrhoid grade, working position, and dietary habits, providing insights for optimizing treatment strategies.
Indexed as
Identifiers
40856750What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.